Evelo Reports the Clinical Hold on EDP1867 Program for the Treatment of Atopic Dermatitis
Shots:
- Evelo has put a hold on the EDP1867 program after its P-I trial failed to demonstrate clinical benefit. The drug showed no clear evidence of benefit after 8wks. across the subset of 15 patients with AD who received the lower dose of the drug
- Evelo will continue to focus on the remaining inflammation programs EDP1815 and EDP2939. The company is planning recruitment in the P-II study of EDP1815 in AD and expected data from this study in Q1’23
- The company reported a faster release capsule cohort to be added to the on-going P-II trial of EDP1815 in atopic dermatitis with data expected in H1’23
Ref: Evola | Image: Evelo
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
